Mumbai, February 21, 2025: Pharmaceutical major Lupin Limited has confirmed the receipt of an Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing unit located in Somerset, New Jersey. The inspection was carried out from January 27 through January 31, 2025.
“Receiving this EIR for our Somerset facility validates our strong quality systems and regulatory readiness,” said Nilesh Gupta, Lupin’s Managing Director.
About Lupin
Lupin Limited is an internationally recognized pharmaceutical leader with its headquarters in Mumbai, India. Serving over 100 markets, the company’s expertise spans generic and branded drugs, biologics, APIs, and complex generics. With a dominant presence in therapeutic areas such as cardiovascular, respiratory, diabetology, anti-infective, CNS, gastroenterology, and women’s health, Lupin runs 15 manufacturing sites and 7 R&D centers globally. Its team of over 23,000 professionals is committed to delivering value through subsidiaries like Lupin Diagnostics, Digital Health, and Manufacturing Solutions.
Sign in to leave a comment.